News
AFMD
5.09
+4.20%
0.21
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Preliminary data from the phase 2 combination study of AFM24 in patients with lung cancer accepted for poster presentation at 2024 American Society of Clinical Oncology Annual Meeting. Affimed N.V. Is a clinical-stage immuno-oncology company.
Barchart · 2d ago
Weekly Report: what happened at AFMD last week (0415-0419)?
Weekly Report · 4d ago
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NASDAQ · 04/17 13:55
Weekly Report: what happened at AFMD last week (0408-0412)?
Weekly Report · 04/15 12:10
Weekly Report: what happened at AFMD last week (0401-0405)?
Weekly Report · 04/08 12:16
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
NASDAQ · 04/04 13:55
Affimed Price Target Cut to $25.00/Share From $30.00 by Wells Fargo
Dow Jones · 04/01 15:48
Affimed Is Maintained at Overweight by Wells Fargo
Dow Jones · 04/01 15:48
Wells Fargo Maintains Overweight on Affimed, Lowers Price Target to $25
Benzinga · 04/01 15:37
Cantor Fitzgerald Reiterates Overweight on Affimed
Benzinga · 04/01 15:15
Affimed Is Maintained at Hold by Stifel
Dow Jones · 04/01 15:03
Affimed Price Target Raised to $5.00/Share From $1.00 by Stifel
Dow Jones · 04/01 15:03
Weekly Report: what happened at AFMD last week (0325-0329)?
Weekly Report · 04/01 12:13
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
TipRanks · 04/01 11:19
Affimed Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/01 10:46
Affimed Price Target Raised to $10.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 04/01 10:46
HC Wainwright & Co. Maintains Buy on Affimed, Raises Price Target to $10
Benzinga · 04/01 10:36
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed
TipRanks · 04/01 10:26
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Affimed (AFMD) and Atara Biotherapeutics (ATRA) have neutral ratings from analysts. The analysts are neither bullish nor bearish on the stocks. Affimed has an analyst consensus of Moderate Buy with a $15.00 average price target.
TipRanks · 04/01 02:20
Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Affimed (AFMD – Research Report) on March 28 and set a price target of $25.00. Zhu remains confident in the potential of the company's lead candidate, AFM13 for Hodgkin Lymphoma.
TipRanks · 03/31 15:05
More
Webull provides a variety of real-time AFMD stock news. You can receive the latest news about Affimed through multiple platforms. This information may help you make smarter investment decisions.
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.